Clinical Equivalence of Two Generic Butenafine Hydrochloride 1% Creams as Compared to Lotrimin Ultra Cream in Patients With Interdigital Tinea Pedis

NCT01119742 | Terminated Phase 1

• 1 other identifier: BTNF-0909
• Study Type: interventional
• Target: 428
• Locations: 0 countries
• Sites: N/A

Brief Summary

To demonstrate comparable safety and efficacy of Taro Pharmaceuticals, Inc butenafine hydrochloride cream 1% test product and Lotrimin Ultra cream (reference listed drug) in the treatment of interdigital tinea pedis, and to show the superiority of the active treatments over that of the placebo (vehicle).

Conditions

Interdigital Tinea Pedis

Keywords

Tinea Pedis; Interdigital

Outcome Measures

Primary Outcomes (1)

• Therapeutic Cure

  Patients with clinical cure and mycologic cure are considered therapeutic cures.

  42 Days

Secondary Outcomes (2)

• Clinical Cure

  42 days

• Mycologic Cure

  42 Days

Study Arms (5)

Butenafine Hydrochloride 1% A

EXPERIMENTAL

1

Drug: Butenafine Hydrochloride 1%

Butenafine Hydrochloride 1% B

EXPERIMENTAL

2

Drug: Butenafine Hydrochloride 1% B

Butenafine Hydrochloride 1%

ACTIVE COMPARATOR

3

Drug: Butenafine Hydrochloride 1%

Vehicle A

PLACEBO COMPARATOR

4

Drug: Vehicle A

Vehicle B

PLACEBO COMPARATOR

5

Drug: Vehicle B

Interventions

Butenafine Hydrochloride 1% DRUG

Twice daily application for 7 days

Butenafine Hydrochloride 1% A

Butenafine Hydrochloride 1% B DRUG

Twice daily application for 7 days

Butenafine Hydrochloride 1% B

Vehicle A DRUG

Twice daily application for 7 days

Vehicle A

Vehicle B DRUG

Twice daily application for 7 days

Vehicle B

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Male or non-pregnant, non lactating females 18 years of age or older.
• Signed informed consent form, which meets all criteria of current FDA regulations and the requirements of the India regulatory authorities.
• If female and of child bearing potential, have a negative urine pregnancy test at the baseline visit,
• A total score of at least six (6) for the following eight (8) clinical signs and symptoms of interdigital tinea pedis: fissuring, erythema, maceration, vesiculation, desquamation/scaling, exudation, pruritus, burning/stinging. In addition the most infected area must have a minimum score of at least 2 for erythema and a minimum score of at least 2 for either pruritus or desquamation/scaling
• A confirmed clinical diagnosis of interdigital tinea pedis.
• The presence of tinea pedis infection, confirmed by the observation of segmented fungal hyphae during a microscopic KOH wet mount examination (potassium hydroxide mount preparation).
• Identification of an appropriate dermatophyte by culture sent to the central laboratory. The appropriate dermatophytes are Trichophyton rubrum, Trichophyton mentagrophytes or Epidermophyton floccosum.

You may not qualify if:

• Use of any of the following within the indicated timeline:
• Oral or injectable steroids within four weeks of the study start.
• Any oral anti-fungals within 4 weeks of the study start.
• Use of topical corticosteroids or any other topical antipruritics on the feet within 72 hours of the study start.
• Any prescription or OTC topical antifungal on the feet within two weeks prior to study entry.
• Use of any antihistamines within 72 hours of the study start.
• Any known hypersensitivity to butenafine or other antifungal agents.
• Evidence of any concurrent dermatophytic infection of toe nails (onychomycosis) or other dermatological condition of the foot that may interfere with the Investigators evaluation of tinea pedis.
• Patients with recurrent tinea pedis (more than 3 infections in the past 12 months) who have been unresponsive to previous antifungal therapy.

Sponsors & Collaborators

• Sun Pharmaceutical Industries, Inc.: lead

MeSH Terms

Conditions

Tinea Pedis

Interventions

butenafine

Condition Hierarchy (Ancestors)

Tinea; Dermatomycoses; Mycoses; Bacterial Infections and Mycoses; Infections; Skin Diseases, Infectious; Foot Dermatoses; Foot Diseases; Skin Diseases; Skin and Connective Tissue Diseases; Pruritus; Skin Manifestations; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: TRIPLE
• Who Masked: PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 6, 2010
• First Posted: May 10, 2010
• Study Start: July 1, 2010
• Primary Completion: March 1, 2011
• Study Completion: July 1, 2011
• Last Updated: May 6, 2014

Record last verified: 2014-05